Haematologica
(Feb 2024)
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
Akriti G. Jain,
Somedeb Ball,
Luis Aguirre,
Najla Al Ali,
David Kaldas,
Sara Tinsley-Vance,
Andrew Kuykendall,
Onyee Chan,
Kendra Sweet,
Jeffrey E. Lancet,
Eric Padron,
David A. Sallman,
Rami Komrokji
Affiliations
Akriti G. Jain
Associate Staff, Leukemia Division, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Somedeb Ball
Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN
Luis Aguirre
Leukemia Fellow, Dana-Farber Cancer Institute, Boston, MA
Najla Al Ali
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
David Kaldas
Internal Medicine Resident, University of South Florida, Tampa, FL
Sara Tinsley-Vance
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Andrew Kuykendall
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Onyee Chan
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Kendra Sweet
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Jeffrey E. Lancet
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Eric Padron
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
David A. Sallman
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Rami Komrokji
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
DOI
https://doi.org/10.3324/haematol.2023.283661
Journal volume & issue
Vol. 999,
no. 1
Abstract
Read online
The patterns of low risk myelodysplastic syndrome (MDS) progression, and the clinical and molecular features of those patterns are not well described. We divided our low risk (LR) MDS patients (n=1914) into 4 cohorts: 1) Patients who remained LR-MDS (LR-LR; n=1300; 68%), 2) Patients who progressed from LR to HR MDS (LR-HR) without AML transformation (n=317; 16.5%), 3) Patients who progressed from LR to HR MDS and then AML (LR-HR-AML; n=124; 6.5%), 4) Patients who progressed from LR MDS to AML directly (LR-AML; n=173; 9%). Risk factors for progression included male gender, low absolute neutrophil count (ANC), low platelet count, high bone marrow (BM) blasts, ferritin >1000 mcg/L, albumin
Published in Haematologica
ISSN
0390-6078 (Print)
1592-8721 (Online)
Publisher
Ferrata Storti Foundation
Country of publisher
Italy
LCC subjects
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website
http://www.haematologica.org
About the journal
WeChat QR code
Close